Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

FZ-AD004

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Shanghai Fudan-Zhangjiang

Drug class:

Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate

Related drugs:

hIMB1636-MMAE (1)

anti TROP-2 antibody therapeutic (0)

fam-trastuzumab deruxtecan-nxki (90)

irinotecan (48)

sacituzumab govitecan-hziy (17)

datopotamab deruxtecan (11)

HRA00129-C004 (3)

sacituzumab tirumotecan (3)

nanoliposomal irinotecan (3)

camptothecin nanosomal (1)

PF-08046044 (1)

rinatabart sesutecan (1)

HA-irinotecan (0)

ICAM‑1 ADC (0)

etirinotecan pegol (0)

irinotecan liposomal (0)

topotecan episcleral (0)

hIMB1636-MMAE (1)

anti TROP-2 antibody therapeutic (0)

›